1. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.
- Author
-
Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, and Viiklepp P
- Subjects
- Adult, Cohort Studies, Coinfection, Female, Humans, Kaplan-Meier Estimate, Male, Microbial Sensitivity Tests, Middle Aged, Mycobacterium tuberculosis drug effects, Proportional Hazards Models, Risk, Sputum microbiology, Treatment Failure, Tuberculosis, Pulmonary diagnosis, Antitubercular Agents therapeutic use, Tuberculosis, Multidrug-Resistant therapy
- Abstract
Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing data and estimated the effect of monitoring strategies on timing of failure detection.We identified studies reporting microbiological response to MDR-TB treatment and solicited individual patient data from authors. Frailty survival models were used to estimate pooled relative risk of failure detection in the last 12 months of treatment; hazard of failure using monthly culture was the reference.Data were obtained for 5410 patients across 12 observational studies. During the last 12 months of treatment, failure detection occurred in a median of 3 months by monthly culture; failure detection was delayed by 2, 7, and 9 months relying on bimonthly culture, monthly smear and bimonthly smear, respectively. Risk (95% CI) of failure detection delay resulting from monthly smear relative to culture is 0.38 (0.34-0.42) for all patients and 0.33 (0.25-0.42) for HIV-co-infected patients.Failure detection is delayed by reducing the sensitivity and frequency of the monitoring method. Monthly monitoring of sputum cultures from patients receiving MDR-TB treatment is recommended. Expanded laboratory capacity is needed for high-quality culture, and for smear microscopy and rapid molecular tests., Competing Interests: can be found alongside this article at erj.ersjournals.com, (The content of this work is copyright the authors or their employers. Design and branding are copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF